Regeneron Q2 rev up 4% to $3.68 bln, Dupixent sales rise 22% to $4.34 bln.

• Q2 2025 revenues up 4% to $3.68 bln • Dupixent sales rise 22% to $4.34 bln • EYLEA HD sales surge 29% to $393 mln • Lynozyfic approved for relapsed/refractory multiple myeloma • Dupixent gets FDA approval for bullous pemphigoid and CSU • Libtayo sBLA for CSCC accepted for priority review • Regeneron in-licenses dual GLP-1/GIP receptor agonist • COURAGE trial interim data show obesity treatment effectiveness

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported robust financial results for the second quarter of 2025, highlighting significant revenue growth and notable regulatory achievements. The company's total revenues increased by 4% to $3.68 billion, driven by strong sales performance across key product lines.

Dupixent, a biologic medicine for the treatment of various inflammatory diseases, saw global sales rise by 22% to $4.34 billion. This growth was supported by recent FDA approvals for bullous pemphigoid and chronic spontaneous urticaria, adding to the drug's already extensive list of indications. Meanwhile, EYLEA HD, a high-dose formulation of aflibercept, experienced a 29% surge in U.S. sales to $393 million, despite a 25% decrease in total franchise sales to $1.15 billion.

Regeneron's oncology portfolio also made significant strides. The company received FDA approval for Lynozyfic in relapsed or refractory multiple myeloma, and Libtayo (cemiplimab) secured a priority review acceptance for its use in adjuvant cutaneous squamous cell carcinoma (CSCC). Additionally, the COURAGE trial, investigating obesity treatment, presented interim data demonstrating the drug's effectiveness.

The company's financial performance was bolstered by strategic in-licensing deals and substantial shareholder returns. Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends, reflecting a commitment to capital allocation that supports long-term value creation.

Regeneron's strong Q2 2025 financial results underscore the company's ability to leverage its diverse pipeline and regulatory achievements to drive revenue growth. As the company continues to invest in its manufacturing capabilities and business development, investors can expect to see further progress in its pipeline and potential for future growth.

References:
[1] https://www.stocktitan.net/news/REGN/regeneron-reports-second-quarter-2025-financial-and-operating-dcwkgplv0cqh.html